Latest news for Wuxi AppTec Co (OTC:WUXIF) Stock

Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, gene therapies, and testing services for medical devices. Its segments comprise WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It generates the majority of its revenue from the WuXi Chemistry segment. Its geographic areas are the PRC, USA, Europe, and the Rest of the world, in which it generates the majority of its revenue from the USA.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Analyst Color

Biotech

Large Cap

Mid Cap

Health Care

Small Cap

Small Business

Analyst Ratings

Tech

General

AVTR

WUXIF

Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates.

Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks

WUXI APPTEC CO REG SHS H by Wuxi Apptec Co Ltd.

Wuxi AppTec Co Ltd

Nintendo ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) has officially announced the &#8220;Nintendo Switch Online: Playtest Program,&#8221; allowing up to 10,000 participants to test a new feature related to the <a href="https://www.benzinga.com/news/earnings/24/08/40138944/nintendos-q1-sales-plummet-could-limited-releases-be-to-blame">Nintendo Switch Online service. </a>
The company has not provided specific details about the new feature, sparking speculation among fans.
See Also:<a href="https://www.benzinga.com/general/gaming/24/09/41074683/in-a-competitive-console-landscape-nintendo-says-it-will-not-get-involved-in-the-game-war"> In A Competitive Console Landscape, Nintendo Says It Will Not &#8216;Get Involved In The Game War&#8217;</a>
<h3 class="wp-block-heading">Participation Details</h3>
To <a href="https://playtest-p.nintendo.com/en-us">participate</a> in the playtest, players must meet the following criteria:
<ul>
<li>Age: Must be at least 18 years old.</li>
<li>Membership: Must have an active Nintendo Switch Online + Expansion Pack subscription.</li>
<li>Location: Participants must have a Nintendo Account registered in Japan, the USA, the United Kingdom, France, Germany, Italy, or Spain.</li>
</ul>
Sign-ups will open Thursday at 6 p.m. PDT and will close on Oct. 15. Participants will need to download &#8220;exclusive software&#8221; to their Nintendo Switch consoles to take part in the playtest, which is scheduled to run from Oct. 23 to Nov. 5.
<h3 class="wp-block-heading">Speculation On The New Feature</h3>
While details about the new feature remain vague, fans are eager to speculate. The company recently launched a gesture-controlled alarm clock, which could indicate a wide range of possibilities, including a sneak peek at features for the highly anticipated Switch 2.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/04/38499828/nintendo-switch-2-reports-leak-magnetic-joy-cons-enhanced-1080p-screen-next-gen-cartridges">Nintendo Switch 2 Reports Leak: Magnetic Joy-Cons, Enhanced 1080p Screen, Next-Gen Cartridges</a></li>
</ul>
Image credits: Shutterstock.

Gaming

News

NTDOY

How To Join Nintendo's Playtest Program To Experience New Switch Online Feature

<a href="https://www.wsj.com/world/middle-east/irans-secret-warning-to-u-s-allies-dont-help-israel-or-youre-next-ccfa5fa0?mod=latest_headlines">https://www.wsj.com/world/middle-east/irans-secret-warning-to-u-s-allies-dont-help-israel-or-youre-next-ccfa5fa0?mod=latest_headlines</a>
DUBAI—Tehran is threatening in secret diplomatic backchannels to target the oil-rich Arab Gulf states and other American allies in the Middle East if their territories or airspace are used for <a href="https://www.wsj.com/world/middle-east/u-s-frustrated-by-israels-reluctance-to-share-iran-retaliation-plans-f132ebc7?mod=article_inline">an attack on Iran</a>, said Arab officials.
Israel has threatened Tehran with a severe reprisal after Iran <a href="https://www.wsj.com/world/middle-east/iran-missiles-israel-overwhelm-defence-a7cbd9af?mod=article_inline">fired about 180 ballistic missiles at Israel</a> earlier this month, with some Israeli officials and commentators pushing for damaging strikes on Tehran's nuclear facilities or oil infrastructure. In that event, Iran has warned it would respond with devastating hits on Israel's civilian infrastructure, and would retaliate against any Arab state that facilitated the attack, the officials said.

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

'Iran's Secret Warning To U.S. Allies: Don't Help Israel, Or You're Next; The Threats Through Diplomatic Channels Have Prompted Arab States To Tell The U.S. That They Won't Aid Any Attack On Iran' - WSJ

Citigroup analyst Vikram Bagri maintains Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) with a Neutral and lowers the price target from $172 to $167.

Price Target

Citigroup Maintains Neutral on Marathon Petroleum, Lowers Price Target to $167

The phrase "the one percent" gets tossed around a lot in conversations about wealth and inequality, whether in politics, protests, or everyday chats. But what does it mean to be in the top 1%? Let's break it down by income and net worth to get a clearer picture of <a href="https://www.benzinga.com/personal-finance/24/09/40711869/how-rich-are-you-heres-the-net-worth-that-defines-upper-middle-and-lower-class">who's part of this exclusive group.</a>
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>This billion-dollar fund has invested in the next big real estate boom, <a href="https://www.benzinga.com/money/fundrise-flagship-fund" target="_blank" rel="noreferrer noopener">here's how you can join for $10.</a></li>
</ul>
What Income Puts You in the Top 1%?
To be in the <a href="https://www.benzinga.com/personal-finance/24/07/39652328/your-income-might-be-upper-class-and-you-dont-know-it-heres-the-salary-needed-to-reach-elite-sta">top 1% of earners</a> in the U.S., a household must bring in at least $591,550 a year. For a single individual, the cutoff is $407,500. Remember, these numbers are averages and can vary depending on where you live. For example, earning that much in New York City might not stretch as far as it does in other parts of the country. The high cost of living, driven by expensive housing, taxes, and everyday expenses, means that a six-figure salary might only cover basic needs in the city. In contrast, in regions with a lower cost of living, such as the Midwest or South, the same income can offer a more comfortable lifestyle with more discretionary spending power.
See Also: <a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved" target="_blank" rel="noreferrer noopener">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a>
The Top 1% by Net Worth
When it comes to net worth, the threshold is even higher. To be part of the top 1% in the U.S., a household's net worth needs to be at least $13.6 million. This measure includes everything you own – homes, investments, savings – minus debts.
Wealth tends to be a lot more unevenly distributed than income. Many households have little to no net worth, while the top tier sits on massive wealth. That's why net worth often gives a clearer picture of someone's financial status than income alone.
Trending: Beating the market through ethical real estate investing' — <a href="https://www.benzinga.com/money/invest-with-roots">this platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a>
Income vs. Net Worth: Which Tells the Real Story?
So, which is more important, income or net worth? It depends on what you're trying to measure. Income is great for understanding how much someone earns in a year, but net worth is the better gauge for long-term financial stability and overall wealth. Someone with a high income might not have a high net worth if they spend a lot or have significant debt, while someone with a lower income but solid investments could be much wealthier.
How Many People Are in the 1%?
As of the latest numbers, there are around 1.3 million households and about 1.8 million individual workers who fall into the top 1% in the U.S. That's a small slice of the population but represents a significant share of the country's wealth and income.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do — <a href="https://www.benzinga.com/money/money-pickle" target="_blank" rel="noreferrer noopener">to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
State-by-State Variations
to the Economic Policy Institute (EPI), the income required to be in the top 1% varies significantly across states.For example:
<ul>
<li>Connecticut has the highest threshold at $952,902</li>
<li>New York follows at $880,000</li>
<li>California comes in third at $805,000</li>
<li>On the lower end, West Virginia at $347,712</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a>
Understanding <a href="https://www.benzinga.com/personal-finance/24/08/40378006/exactly-how-much-money-do-you-need-to-be-rich-heres-a-look-at-the-numbers">who makes up this elite group</a> isn't just about how much you earn right now but also what you've built over time.&nbsp;
Maybe you're not in the top 1%, or maybe you are – everyone's situation is different. Either way, <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">talking with a financial advisor</a> can be really helpful. They can guide you on where you stand and how to make the best decisions for your financial future, whether you're growing your wealth or looking to manage what you've got.
This story has been updated to reflect more current income threshold numbers.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace — <a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv" target="_blank" rel="noreferrer noopener">here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Personal Finance

Are You Rich Enough To Be In The Top 1%? Here's Both The Income And Net Worth You Need to Rank Among The Wealthiest

High-rolling investors have positioned themselves bearish on American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AXP often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for American Express. This is not a typical pattern.
The sentiment among these major traders is split, with 25% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $29,062, and 7 calls, totaling $424,370.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $140.0 and $290.0 for American Express, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for American Express's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across American Express's significant trades, within a strike price range of $140.0 to $290.0, over the past month.
<h3>American Express Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728589561_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$141.15</td>
<td>$139.2</td>
<td>$139.2</td>
<td>$140.00</td>
<td>$125.2K</td>
<td>147</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$77.35</td>
<td>$76.4</td>
<td>$76.88</td>
<td>$200.00</td>
<td>$76.8K</td>
<td>176</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.95</td>
<td>$8.85</td>
<td>$8.95</td>
<td>$290.00</td>
<td>$53.7K</td>
<td>1.3K</td>
<td style="text-align: right;">88</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$56.95</td>
<td>$56.9</td>
<td>$56.9</td>
<td>$240.00</td>
<td>$51.2K</td>
<td>7.7K</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$23.25</td>
<td>$23.2</td>
<td>$23.25</td>
<td>$250.00</td>
<td>$41.8K</td>
<td>1.4K</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About American Express</h3>
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
Having examined the options trading patterns of American Express, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of American Express</h3>
<ul>
<li>Currently trading with a volume of 1,202,163, the AXP's price is down by -0.3%, now at $270.61. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for American Express, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Looking At American Express's Recent Unusual Options Activity

Financial giants have made a conspicuous bullish move on Lyft. Our analysis of options history for Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $144,622, and 4 were calls, valued at $116,700.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $12.0 to $13.5 for Lyft over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Lyft's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Lyft's substantial trades, within a strike price spectrum from $12.0 to $13.5 over the preceding 30 days.
<h3>Lyft Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728589556_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$0.52</td>
<td>$0.51</td>
<td>$0.52</td>
<td>$12.50</td>
<td>$42.4K</td>
<td>8.5K</td>
<td>898</td>
</tr>
<tr>
<td>LYFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$0.57</td>
<td>$0.55</td>
<td>$0.57</td>
<td>$12.50</td>
<td>$38.2K</td>
<td>8.5K</td>
<td>2.5K</td>
</tr>
<tr>
<td>LYFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$0.55</td>
<td>$0.52</td>
<td>$0.55</td>
<td>$12.50</td>
<td>$34.9K</td>
<td>8.5K</td>
<td>1.5K</td>
</tr>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$0.34</td>
<td>$0.31</td>
<td>$0.34</td>
<td>$12.50</td>
<td>$34.0K</td>
<td>8.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>LYFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$0.31</td>
<td>$0.29</td>
<td>$0.29</td>
<td>$12.00</td>
<td>$29.0K</td>
<td>7.4K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>

<h3>About Lyft</h3>
Lyft is the second-largest ride-sharing service provider in the us and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
<h3>Where Is Lyft Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,939,222, the LYFT's price is down by -1.56%, now at $12.31. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Lyft, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

LYFT

Looking At Lyft's Recent Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Petrobras Brasileiro.
Looking at options history for Petrobras Brasileiro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $129,476 and 5, calls, for a total amount of $298,150.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $3.0 to $15.0 for Petrobras Brasileiro over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Petrobras Brasileiro's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Petrobras Brasileiro's whale trades within a strike price range from $3.0 to $15.0 in the last 30 days. 
<h3>Petrobras Brasileiro Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728589551_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.35</td>
<td>$0.34</td>
<td>$0.34</td>
<td>$15.00</td>
<td>$68.0K</td>
<td>17.7K</td>
<td>2.0K</td>
</tr>
<tr>
<td>PBR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$13.35</td>
<td>$11.4</td>
<td>$12.0</td>
<td>$3.00</td>
<td>$60.0K</td>
<td>300</td>
<td>170</td>
</tr>
<tr>
<td>PBR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$13.35</td>
<td>$11.4</td>
<td>$11.92</td>
<td>$3.00</td>
<td>$59.6K</td>
<td>300</td>
<td>170</td>
</tr>
<tr>
<td>PBR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$13.35</td>
<td>$11.4</td>
<td>$11.91</td>
<td>$3.00</td>
<td>$59.5K</td>
<td>300</td>
<td>120</td>
</tr>
<tr>
<td>PBR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$12.15</td>
<td>$11.4</td>
<td>$11.9</td>
<td>$3.00</td>
<td>$59.5K</td>
<td>300</td>
<td>370</td>
</tr>
</tbody>
</table>

<h3>About Petrobras Brasileiro</h3>
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on exploration and production of oil and gas in Brazilian offshore fields. Production in 2023 was 2.8 million barrels of oil equivalent a day (80% oil production), and reserves stood at 10.9 billion boe (85% oil). At end-2023, Petrobras operated 10 refineries in Brazil with capacity of 1.8 million barrels a day and distributes refined products and natural gas throughout Brazil.
In light of the recent options history for Petrobras Brasileiro, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Petrobras Brasileiro</h3>
<ul>
<li>Trading volume stands at 7,561,012, with PBR's price up by 1.83%, positioned at $14.91.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 28 days.</li>
</ul>
<h3>Professional Analyst Ratings for Petrobras Brasileiro</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $19.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has elevated its stance to Overweight, setting a new price target at $19. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Petrobras Brasileiro, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Petrobras Brasileiro Options Trading: A Deep Dive into Market Sentiment

WIIM

Triumph Group shares are trading higher following a report suggesting the company is exploring a sale.

GSK and Pfizer shares are trading lower amid possible declining Respiratory Syncytial Virus vaccine sales after the CDC recommended a narrow age cohort for routine use.

Trading Ideas

NIVF

NIVF TW Opportunities Master Fund II, L.P. Discloses 9.9% Passive Stake in NewgenIVF Group Ltd as of October 4

AngloGold Ashanti shares are trading higher after JP Morgan raised its price target on the stock from $32 to $37.

Sunrun shares are trading lower. Jefferies cut its price target on the stock from $31 to $29.

As the <a href="https://www.benzinga.com/earnings">third-quarter earnings season</a> kicks off, one analyst examined the sectors anticipated to perform well and those likely to be left in the dust.
The Data: Scotiabank analyst Hugo Ste-Marie previewed third-quarter earnings in a note published Wednesday.
The analyst believes that earnings will &#8220;nosedive&#8221; in a temporary blip, while also saying that investors will punish earnings misses less this quarter than last quarter.
The S&amp;P 500, tracked by SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), is expected to register a modest 0.5% earnings growth quarter over quarter and 3.9% on the year. The latter figure came in at a much higher 12% last quarter.
&#8220;After a huge run-up in equity prices, investors will likely scrutinize Q3 numbers and earnings guidance, which could lead to sharp reactions if they are not pleased,&#8221; Ste-Marie said. &#8220;Still, the Q3 earnings bar has been reduced since June, and given that economic activity remains robust, another earnings beat could be around the corner.&#8221;
Also Read: <a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne">Elon Musk May Unveil Tesla&#8217;s Robotaxi, But Consumers Respond With &#8216;Ehhh,&#8217; New Study Reveals Skepticism, Need For Trust-Building</a>
The analyst also noted that this quarter&#8217;s earnings will serve as another proxy for consumer spending health.
&#8220;Similar to last quarter, we will continue to watch some key bellwether consumer stocks and banks to spot any change in consumer behavior or, rather, more visible cracks in consumer spending/bad loans,&#8221; Ste-Marie said. &#8220;When we look at high-frequency data, such as the Johnson Redbook index, which is tracking weekly retail sales, spending remains overall healthy (while the discount category performs well, department stores sales are struggling).&#8221;
Additionally, earnings could provide key information on the impact of Hurricanes Helene and Milton.
Sector by Sector: The top projected sector is technology, with the analyst anticipating a 15% increase in earnings year over year. Communications and healthcare are also expected to be top performers.
Conversely, the energy sector is projected to experience a 24% decline in profits year over year, with materials also expected to show a reduction in profits.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41276280/hurricane-milton-closes-multiple-florida-airports-over-3-000-flights-canceled-and-delayed-10-air">Hurricane Milton Closes Multiple Florida Airports, Over 3,000 Flights Canceled And Delayed: 10 Airline Stocks That Could Be Hit Hardest</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Previews

Q3 Earnings Preview: Analyst Predicts Tech Will Triumph While Energy Will Struggle

Barclays analyst Tim Long maintains SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) with a Overweight and raises the price target from $236 to $256.

SBAC

Barclays Maintains Overweight on SBA Comms, Raises Price Target to $256

Triumph Group Shares Resume Trade

Iamgold shares are trading higher after National Bank Financial upgraded the stock from Sector Perform to Outperform and raised its price target from $8.5 to $11.

SS&amp;C Techs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) has outperformed the market over the past 10 years by 1.26% on an annualized basis producing an average annual return of 13.18%. Currently, SS&amp;C Techs Hldgs has a market capitalization of $18.12 billion. 
Buying $100 In SSNC: If an investor had bought $100 of SSNC stock 10 years ago, it would be worth $339.01 today based on a price of $73.82 for SSNC at the time of writing.
<h3>SS&amp;C Techs Hldgs's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728588675_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SSNC

Here's How Much $100 Invested In SS&C Techs Hldgs 10 Years Ago Would Be Worth Today

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.55% on an annualized basis producing an average annual return of 13.48%. Currently, AbbVie has a market capitalization of $341.52 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $357.27 today based on a price of $193.40 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728588670_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

In the current market session, Incyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock price is at $64.92, after a 1.28% drop. However, over the past month, the company's stock went up by 2.46%, and in the past year, by 12.69%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1728588647_0.png" alt="Past Year Chart" />

<h3>Incyte P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 50.65 in the Biotechnology industry, Incyte Inc. has a higher P/E ratio of 160.39. Shareholders might be inclined to think that Incyte Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728588647_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

INCY

A Look Into Incyte Inc's Price Over Earnings

Barclays analyst Brendan Lynch maintains W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) with a Equal-Weight and raises the price target from $54 to $56.

Barclays Maintains Equal-Weight on W.P. Carey, Raises Price Target to $56

Beijing's Sino Biological completed its $48 million acquisition of Vancouver-based SignalChem Biotech. Additionally, Biocytogen Pharmaceuticals signed a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG.

Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals

Harding Loevner Global Equity Composite Q1 2024 Report

Harding Loevner Global Equity ADR Composite Q1 2024 Report

Harding Loevner Global Developed Markets Equity Composite Q1 2024 Report

Harding Loevner Chinese Equity Composite Q1 2024 Report

Harding Loevner Emerging Markets Equity Composite Q1 2024 Report

In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson.

Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal

Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million, and up to more than $2 billion in milestones.

Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal

Week In Review: ImmuneOnco Out-Licenses 2 Antibodies In $2 Billion Deal

Chinese biotechs gain as drugmakers targeted in new security bill said to mull divestments

AAGIY

AAIGF

ADBE

AMZN

ASML

ASMLF

BABA

BABAF

BAIDF

BGNE

BHPLF

BIDU

BOLSY

BUGDF

BUHPF

CHVKF

CHVKY

CSCO

GLOB

GOOG

GOOGL

IDYA

IMAB

IPSEY

IVBXF

JDCMF

LOOP

LYPHF

MELI

MSFT

NETTF

NFLX

NHNCF

NTES

NVDA

PCCYF

RTNTF

RTPPF

SAPGF

SBGSF

SBGSY

SNEJF

SONY

SRNMF

SSNLF

TCEHY

TCOM

TCTZF

TRPCF

VNKEF

VRTX

WUXAY

WXIBF

WXXWY

ZLAB

Wuxi AppTec Co

Goldman Sachs analysts are identifying a substantial opportunity in the manufacturing sector for new obesity therapeutics as demand escalates <a href="https://www.benzinga.com/topic/weight-loss">for these treatments</a>.



Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting it could expand up to $400 billion.



Dominant market players like Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) conduct much of their production in-house but are expected to increasingly outsource this business unit to meet the burgeoning demand for weigh-loss medications.



&#8220;We estimate the long term potential market size for GLP-1 manufacturing is ~$10bn and the role of outsourcing will likely increase with volumes.&#8221;



Despite the current dominance of Eli Lilly and Novo Nordisk in the obesity treatment market, Goldman Sachs believes &#8220;increasing volumes along with new entrants into the space will lead to about 50% outsourcing and a about $5bn opportunity for outsourced providers in 2030.&#8221; Both companies have announced capacity expansions to meet growing demand.



According to Goldman Sachs, Eli Lilly&#8217;s tirzepatide, approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, is forecasted to achieve around $55 billion in sales by 2030, potentially becoming one of the best-selling pharmaceuticals ever.



<h3 class="wp-block-heading">7 Biotech Stocks Benefiting From Obesity Drug Outsourcing Opportunity</h3>



<ul>
<li>Avantor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>): Avantor is poised to benefit from the surge in demand, especially for oral tablet active pharmaceutical ingredients (APIs), as Goldman Sachs anticipates 45% of GLP-1 drugs will be orally administered by 2030. The focus will shift towards API synthesis (upstream) over fill and finish services (downstream).</li>



<li>Thermo Fisher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): Thermo Fisher, already involved in fill and finish services for Novo Nordisk, is expected to see growth in its contract development and manufacturing organization (CDMO) business due to increasing GLP-1 production demands.</li>



<li>Water Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) and Agilent Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>): Both companies could gain from the need for more high-performance liquid chromatography (HPLC) instruments and columns as production scales up.</li>



<li>Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>): Danaher is noted to benefit from the entire production chain for biologically produced GLP-1 drugs, which require more upstream solutions like cell lines and culture media.</li>



<li>Wuxi AppTec Co. Ltd (OTCPK: WUXIF): As of August 2023, Wuxi AppTec was a key CDMO for 11 GLP-1 drugs, including clinical and commercial-stage projects, indicating a strong position in the market.</li>



<li>Asymchem Laboratories: Specializing in small molecule drug manufacturing, Asymchem is actively engaged in developing leading oral GLP-1 programs, positioning it well in the growing market.</li>
</ul>



Read Now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37663625/royal-caribbean-carnival-cruise-toward-the-next-wave-of-the-rising-tide-goldman-sac">Royal Caribbean, Carnival Cruise Toward &#8216;The Next Wave of the Rising Tide&#8217;: Goldman Sachs</a>



Photo via Shutterstock.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Wuxi AppTec Co

News

Latest news for Wuxi AppTec Co (OTC:WUXIF) Stock

Wednesday, March 13, 2024